Generates revenue primarily from out-licensing and distribution agreements for its A3 adenosine receptor (A3AR) small-molecule drug candidates, including upfront payment amortization, license fees, and milestone-related income. The core value driver is advancing its clinical-stage pipeline to enable partner-led commercialization and potential future royalties.
